Use access key #2 to skip to page content.




February 26, 2014 – Comments (1) | RELATED TICKERS: GALT

Finally, clinical-stage drug developer Galectin Therapeutics (NASDAQ: GALT  ) jumped 15% after announcing a preclinical study that supports its investigational new drug application for GR-MD-02 in nonalcoholic steatohepatitis, or NASH. Specifically, hyaluronic acid, a biomarker of liver fibrosis, which is common with NASH, was reduced by 33% in animals treated with GR-MD-02 compared to untreated animals. As we've witnessed withIntercept Pharmaceuticals' recent $200-per-share move following its midstage results on obeticholic acid, there's a huge market for treating advanced NASH cases (approximately 6 million people), so these early results could be encouraging. Keep in mind, though, that how a drug responds in animal testing can be completely different from how it responds in human clinical trials. Don't get too excited just yet.

1 Comments – Post Your Own

#1) On February 26, 2014 at 5:34 PM, EnigmaDude (59.36) wrote:

This news came out first thing this morning yet the stock barely moved. Another "buy the rumor, sell the news" story?

Report this comment

Featured Broker Partners